Skip to content

Study · Randomized controlled trial · 2010

2 results

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.

Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt EH

Fertility and sterility9 Jan 2009Cited by 90 (Europe PMC)

PMID19135657 (opens in a new tab)DOI10.1016/j.fertnstert.2008.09.064 (opens in a new tab)PepBankPUB-19135657
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with leiomyomas, triptorelin significantly reduced myoma volume by 33.2% from baseline.

    In plain wordsIn premenopausal women with fibroids, triptorelin significantly reduced fibroid volume by 33.2% from baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMyoma volume
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 12 weeksAs given in this study (human).

    Measurements

    Myoma volume reduction
    33.2%
    triptorelin

    Source sentences

    Summary
    Total myoma volume decreased by 45.6% in group A and 33.2% in group B. Reductions in myoma volume in the two groups were statistically significant.
    2 context sentences
    Summary · context
    A total of 70 subjects with a single uterine myoma measuring >or=5 cm.
    Summary · context
    Group B received triptorelin (3.75 mg/mo) for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with leiomyomas, triptorelin significantly reduced serum hormone levels by the end of treatment.

    In plain wordsIn premenopausal women with fibroids, triptorelin significantly reduced blood hormone levels from baseline by the end of treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseSerum hormone levels
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg/mo · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The serum level of hormones significantly decreased in group B by the 12th week of treatment.
    2 context sentences
    Summary · context
    A total of 70 subjects with a single uterine myoma measuring >or=5 cm.
    Summary · context
    Group B received triptorelin (3.75 mg/mo) for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedNot applicableNCT01280045

Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy

University of Sao Paulon = 5Jan 2011 to Jan 2015

UTERINE LEIOMYOMA

Trial pageClinicalTrials.govUpdated 13 Aug 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.